Recall | Medicines | 21/04/2016

The marketing authorization holder has informed its supplied customers in a letter dated 20.04.2016 that the marketing authorizations of medicinal products containing fusafungin (Locabiosol / Bioparox / Locabiotal / Fusaloyos as oral spray, nasal spray or as solution) will be revoked within the EU.These medicines are used for the treatment of upper respiratory tract infections such as rhinopharyngitis.In Austria, this concerns "Locabiosol 1 % - Dosierspray", which is now being recalled prior to the cancellation of the marketing authorization.

Name of the medicinal product Locabiosol 1 % -Dosierspray
Marketing authorisation number(s) 1-22703
Marketing authorisation holder Servier Austria GmbH
Batch number(s) Alle in der Laufzeit befindlichen Chargen
Classification of the recall3
BASG reference number INS - 640.001 - 1684

Further inquiry note